News

Some states offer great homestead protection, but most provide an inadequate shield. Learn how to protect your greatest assets.

A 5-expert panel continues their conversation on atopic dermatitis, discussing patient-centered care and key takeaways.

Results of a recent study show RECAP's impact on adult Asian patients with AD.

This week’s collection of the latest dermatologic studies includes case reports of onychocytic matricoma, congenital triangular alopecia treated with 5% topical minoxidil, systemic therapy usage in vulvar lichen sclerosus and vulvovaginal lichen planus, and dose escalation of interleukin inhibitors in Japanese patients with psoriasis.

Care Messenger helps to expand care delivery and respond to growing patient needs without placing additional strain on clinicians.

In recognition of Skin Cancer Awareness Month, Dermatology Times is reviewing research and strides in skin cancer treatment over the last decade.

Discover pearls on caring for patients with STDs, using dermatopathology in SOC, managing inflammatory skin conditions in women, and ensuring patients are able to access care needed.

Click here to read more and answer our quiz questions in recognition of Skin Cancer Awareness Month.

Keep up with the latest headlines in dermatology from the past week, including Johnson & Johnson's acquisition of Proteologix, a review of sunscreen approvals and efficacy, and more.

In case you missed it, this week we had news about roflumilast foam's efficacy in diverse hair types of seborrheic dermatitis, Lindus Health's new partnership to evaluate a benzoyl peroxide alternative, sonelokimab advancing to phase 3 for HS, and more.

Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.

Clearly Me uses portraiture to spotlight the journeys of psoriasis patients Katie Lowes, DaQuane Cherry, Ayesha Patrick, and Joanna “JoJo” Pomerantz.

It is important dermatologists learn to recognize the clinical findings of dermatophytomas and distinguish them from other onychomycosis subtypes because the recommended treatments differ.

Earlier this week, we shared our second Skin Cancer Awareness Month quiz. Review the answers and your responses below.

Researchers reviewed research into the medical and toxicological viewpoints of tattooing the skin from the past decade.

A recent study spotlights an opportunity for interdisciplinary collaboration between dermatologists and orthodontists.

VELA is the first phase 3 hidradenitis suppurativa trial to evaluate HiSCR75 as the primary end point.

Bristol Myers Squibb announced 70% of patients maintained significant improvement after 4 years with no new safety concerns.

Acinonyx Bio's topical cream, ACX, targets Propionibacterium acnes.

The results are both confirmatory and extend the response results from a prior phase 3 trial known as FLASH.

Clinicians, especially those who see patients with inflammatory and pigmentary disorders, should incorporate alcohol use disorder screening measures into all patient visits.

In this month’s Cosmetic Conundrums column, explore what dermatology clinicians need to know about false eyelashes to help prevent infections or contact dermatitis.

Researchers have developed a clinical decision support model using machine learning to assist health care providers in predicting diagnoses of hidradenitis suppurativa.

These results are indicative of the need for dermatologists to discuss social media misinformation and low quality information with their patients.

Researchers say addressing socioeconomic differences may be the key to addressing this disparity.

Dermatology PAs and NPs continue to address the demand-supply mismatch in dermatologic care and can significantly bring their skills within the primary care model.

The needs assessment surveyed patients’ stage of treatment, radiation-induced dermatologic adverse effects, and over-the-counter products and home remedies that were used.

Researchers found that abrocitinib demonstrated rapid, sustained, and deep improvements in several important domains of itch-dominant AD.

In a comparison of pediatric dermatologists versus AI, dermatologists primarily exhibited greater performance.

Mark Lebwohl, MD, and Saakshi Khattri, MD, discuss the evolving landscape of plaque psoriasis treatments over the past year.